Oral Fluoropyrimidines: Are They the Equivalent of Parenteral Infusional 5-Fluorouracil?

REFERENCES

• Pazdur R., Douillard J. Y., Skillings J. R., et al. Multicenter Phase III Study of 5-Fluorouracil (5-FU) or UFT in Combination with Leucovorin (LV) in Patients with Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 263a, (abstract 1009)
   Google Scholar
• Twelves C., Harper P., Van Cutsem E., Thibault A., et al. A Phase III Trial (S014796) of Xeloda (Capecitabine) in Previously Untreated Advanced Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 263a, (abstract 1010)
   Google Scholar
• Carmichael J., Popiela T., Radstone D., et al. Randomized Comparative Study of ORZEL Oral Uracil/Tegafor (UFT) Plus Leucovorin (LV) Versus Parenteral 5 Fluorouracil (5FU) Plus LV in Patients with Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 264a, (abstract 1015)
   Google Scholar
• A Randomized Open-Label Phase III Study of a 28 Day Oral Regimen of 5-Fluorouracil Plus 776C85 Versus Intravenous 5-Fluorouracil Plus Leucovorin as First-Line Therapy in Patients with Metastatic/Advanced Colorectal Carcinoma. FUMA 3008
   Google Scholar
• Lokich J. Pharmacokinetic Modulation of 5-Fluorouracil: Emulating Continuous Infusion?. Cancer Invest 1999; 17(7)543–544
   PubMed Web of Science ®Google Scholar
• Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5FU Plus Eniluracil to Weekly 24 Hour Infusion in Previously Untreated Patients with Advanced Colorectal Cancer, ECOG no. 5296
   Google Scholar
• Fraile R. J., Baker L. H., Buroker T. R., et al. Pharmacokinetics of 5FU Administration Orally, by Rapid Intravenous and by Slow Infusion. Cancer Res. 1980; 40: 2223–2228
   PubMed Web of Science ®Google Scholar
• Lokich J. J., Bothe A., Fine N., Perri J. Phase I Study of Protracted Venous Infusion of 5-Fluorouracil. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in Cancer: Efficacy of Intravenous Continuous Infusion of Fluorouracil Compared with Bolus Administration in Advanced Colorectal Cancer. J. Clin. Oncol. 1998; 16(1)301–308
   PubMed Web of Science ®Google Scholar
• De Gramont A., Bosset J., Milan C., et al. Randomized Trial Comparing Monthly Low-Dose Leucovorin-5-Fluorouracil Bolus with Bi-monthly High Dose Leucovron-5-Flourouacil Bolus Plus Continuous Infusion for Advanced Colorectal Cancer. A French Intergroup Study. J. Clin. Oncol. 1997; 15: 808–815
   PubMed Web of Science ®Google Scholar
• Aranda S., Diaz-Rubio E., Cervantos A., et al. Randomized Trial Comparing Monthly Low-Dose Leucovorin and Fluorouracil Bolus with Weekly High-Dose 48 Hour Continuous Infusion Fluorouracil for Advanced Colorectal Cancer. A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) Study. Ann. Oncol. 1999; 9: 727–731
   Web of Science ®Google Scholar
• Harris B. E., Song R., Song S. J., et al. Relationship Between Dihydropyrimidine Dehydrogenase Activity and 5-FU Levels with Evidence of Circadian Variation of Enzyme Activity and Plasma Drug Levels in Cancer Patients Receiving 5-FU. Cancer Res. 1994; 85: 665–668
   Google Scholar
• Lokich J. J., Moore C. Chemotherapy Associated Palmar-Plantar Erythrodysesthesia Syndrome. Ann. Intern. Med. 1984; 101: 789–800
   PubMedGoogle Scholar
• Pazdur R., Lassere Y., Rhodes V., et al. Phase II Trial of Uracil and Tegafur Plus Oral Leucovorin: An Effective Oral Regimen in the Treatment of Metastatic Colorectal Carcinoma. J. Clin. Oncol. 1994; 12: 2296–2300
   PubMed Web of Science ®Google Scholar
• Caudry M., Bonnel C., Floquet C., et al. A Randomized Study of the Bolus Fluorouracil Plus Folinic Acid Versus 21-Day Fluorouracil Infusion Alone or in Association with Cyclophosphamide and Mitomycin-C in Advanced Colorectal Carcinoma. Am. J. Clin. Oncol. 1995; 18(2)118–125
   PubMed Web of Science ®Google Scholar
• Leichman C. G., Fleming T. R., Muggia F. M., et al. Phase III Study of 5FU and Its Modulation in Advanced Colorectal Cancer. A Southwest Oncology Group (SWOG) Study. J. Clin. Oncol. 1995; 13: 1303–1311
   PubMed Web of Science ®Google Scholar
• Poplin E., Benedetti N., Estes D., et al. Phase III Randomized Trial of Bolus 5FU/Leucovorin/Lavamisole Versus 5FU Continuous Infusion/Levamisole as Adjuvant Therapy for High Risk Colon Cancer (SWOG 9415/INT-0153). Am. Soc. Clin. Oncol. 2000; 19, (abstract 931)
   Google Scholar
• Saini A., Cunningham D., Norman A. R., et al. Multicenter Randomized Trial of Protracted Venous Infusion (PVI) 5FU Compared to 5FU/Folinic Acid (5FU/FA) as Adjuvant Therapy for Colorectal Cancer. Am. Soc. Clin. Oncol. 2000; 19, (abstract 928)
   Google Scholar